Nivalis Therapeutics, Inc. (NASDAQ:ALPN) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

ALPN has been the topic of several other reports. ValuEngine raised shares of Nivalis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Ladenburg Thalmann Financial Services started coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $5.75.

Nivalis Therapeutics (NASDAQ ALPN) traded down 0.77% during trading on Thursday, hitting $10.27. 19,831 shares of the stock were exchanged. The firm’s market capitalization is $6.84 million. Nivalis Therapeutics has a 12-month low of $7.20 and a 12-month high of $26.08. The stock has a 50 day moving average price of $10.94 and a 200-day moving average price of $9.68.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong Sell” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Get a free copy of the Zacks research report on Nivalis Therapeutics (ALPN)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with's FREE daily email newsletter.